1,554,189 Shares in USANA Health Sciences, Inc. $USNA Bought by BlackRock Inc.

Key Points

• BlackRock acquired 1,554,189 USANA shares worth approximately $33.2 million, giving it an 8.42% stake. Institutional investors collectively own 54.25% of the company.
• USANA’s latest quarterly results missed expectations, with a loss of $0.07 per share versus analysts’ projected profit of $0.43 and revenue of $223.27 million versus $235 million expected.
• Shares opened at $14.01, near their 52-week low, while analyst sentiment remains negative: Weiss Ratings maintained a sell rating, and Zacks Research downgraded the stock to “strong sell.”

BlackRock Inc. bought a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,554,189 shares of the company's stock, valued at approximately $33,182,000. BlackRock Inc. owned approximately 8.42% of USANA Health Sciences at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Versant Capital Management Inc lifted its holdings in shares of USANA Health Sciences by 1,472.3% during the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company's stock valued at $34,000 after purchasing an additional 1,487 shares in the last quarter. National Bank of Canada FI increased its stake in USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company's stock worth $53,000 after purchasing an additional 1,201 shares in the last quarter. State of Wyoming bought a new stake in USANA Health Sciences during the 1st quarter worth approximately $57,000. Tower Research Capital LLC TRC raised its holdings in USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock worth $73,000 after buying an additional 1,901 shares during the period. Finally, Parallel Advisors LLC raised its holdings in USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company's stock worth $76,000 after buying an additional 3,589 shares during the period. 54.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Brent Neidig sold 5,002 shares of the company's stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.82% of the stock is owned by insiders.

Wall Street Analyst Weigh In

USNA has been the topic of several recent research reports. Weiss Ratings reissued a "sell (d)" rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Zacks Research downgraded shares of USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of "Sell".

USANA Health Sciences Stock Down 1.8%

Shares of USNA stock opened at $14.01 on Wednesday. The firm has a 50 day moving average of $18.65 and a 200-day moving average of $18.69. The company has a market cap of $258.90 million, a price-to-earnings ratio of -11.58, a price-to-earnings-growth ratio of 1.56 and a beta of 0.68. USANA Health Sciences, Inc. has a 52 week low of $12.57 and a 52 week high of $32.29.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Analysts anticipate that USANA Health Sciences, Inc. will post 0.76 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source